Search Term:

*


September 28, 2016: A series of new product launches being planned for Biotech Week Boston in October

November 21, 2017: Introducing a new and robust solution for the economic clarification of mAb (monoclonal antibody) cell cultures without the need for centrifugation or process additives

October 5, 2016: New collaboration to deliver complete solutions for industrial-scale bioreactor expansion of human Mesenchymal Stem/Stromal Cells (hMSCs), to accelerate product development, reduce clinical translation timelines and streamline the commercialization pathway for stem cell-based therapies

October 4, 2016: Multiple breakthrough technologies announced to enable integrated, process-scale continuous production of biotherapies in single-use format

June 15, 2015: Announcing Pall's signing of an exclusive license for acoustic wave separation (AWS), a disruptive technology from FloDesign Sonics (FDS) for cell culture clarification for both fed-batch and perfusion applications

October 13, 2016: Introducing a reliable, robust, universal single-use fluid handling connector - a genderless technology for the sterile connection of two fluid paths even in uncontrolled environments

March 31, 2021: New acquisition will help support single-use technology demand driven by COVID-19

April 1, 2021: Major capacity expansion underway to support increase in industry demand

December 13, 2017: Several recent and upcoming high-profile partnership announcements announced to help advance the drug production industry through key technology innovations

September 25, 2017: Announcing three new additions to the Allegro™ single-use chromatography and Cadence™ continuous bioprocessing product portfolios, to be showcased this week at the BPI 2017 event in Boston

January 29, 2018: New name reinforces Pall's commitment to providing standard configurable single-use, stainless steel and hybrid technologies for fed-batch and continuous processes across upstream, downstream and formulation and filling applications in biotech

September 11, 2018: Pall and Aetos partner to combine bioreactors, mixing and storage, and downstream technologies with cell lines and manufacturing processes for expedited biosimilars development

November 9, 2017: New training courses starting early 2018 focused on continuous bioprocessing advances will detail the state of the industry, and the advantages and practical implications of transitioning from batch to semi- or fully-continuous bioprocess methodologies

July 23, 2018: New partnership to integrate novel biologics and biosimilars process know-how and regulatory experience from molecule selection to full commercialization, with efficient upstream and downstream process equipment and facility design solutions for manufacturers

December 9, 2016: Cadence Acoustic Separator wins the BioProcess International (BPI) Award for best downstream processing application

March 19, 2019: New lab will serve as a dedicated platform where the industry can access shared resources including equipment, expertise and project work to find innovative solutions to manufacturing needs for biologic medicines, such as cell-based immunotherapies

April 29, 2019: Freeline's (AAV) manufacturing platform and Pall’s iCELLis bioreactor system combine to achieve commercial-scale and high quality production of AAV gene therapy vectors

April 26, 2016: This new product will eliminate reliance on centrifugation for cell culture clarification, reducing buffer requirements by around 75%, and create a continuous feed stream for direct integration with Pall's full portfolio

September 11, 2015: Pall manufacturing facility in Ilfracombe, UK is singled out for its exceptional health and safety management systems

October 20, 2015: A total of four new and updated products to be unveiled at the event, with Pall experts on hand to discuss advances that continuously improve bioprocesses for customers